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Abstract: Despite the benefits of red blood cell (RBC) transfusion therapy, it can render patients vulnerable to iron overload. The excess iron deposits in various body tissues cause severe complications
and organ damage such as cardiotoxicity and mold infections. Clostridioides difficile infection (CDI)
is the most common cause of nosocomial diarrhea among cancer patients and is associated with
significant morbidity and mortality. Our study aims to determine the role of iron overload and the
effects of iron chelators on CDI. Our results demonstrated that iron (Fe3+ ) stimulated the growth of
C. difficile with increased colony formation units (CFU) in a dose-dependent manner. Exposure to
excess iron also increased the gene expression levels of tcdA and tcdB. The production of C. difficile
toxin A, necessary for the pathogenesis of C. difficile, was also elevated after iron treatment. In the presence of excess iron, C. difficile becomes less susceptible to metronidazole with significantly elevated
minimum inhibitory concentration (MIC) but remains susceptible to vancomycin. Iron-stimulated
colony formation and production of C. difficile toxins were effectively diminished by iron chelator
deferoxamine co-treatment. Incorporating iron overload status as a potential factor in developing
a risk prediction model of CDI and antibiotic treatment response may aid clinical practitioners in
optimizing CDI management in oncology patients.
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1. Introduction
Clostridioides difficile, a Gram-positive, spore-forming, obligately anaerobic bacterium,
is the leading cause of healthcare-associated infectious diarrhea, ranging from mild diarrhea
to pseudomembranous colitis and toxic megacolon, with an increasing incidence and
associated mortality [1]. C. difficile infection (CDI) is a toxin-mediated disease, and the
production of two clostridial toxins (TcdA and TcdB) are considered the cause of CDI
symptoms by traditional C. difficile strains. In the early 2000s, a new epidemic strain
BI/NAP1 ribotype 027 began circulating and causing severe infections [2]. This strain was
characterized by being fluoroquinolone-resistant, having a third toxin known as binary
toxin, and producing increased amounts of TcdA and TcdB due to deletion of the tcdC gene,
which is a negative regulator of toxin production [3,4].
C. difficile can cause infections in any patient; however, there are specific risk factors
that are strongly associated with CDI infection. These factors include exposure to antibiotic
therapy or proton pump inhibitors, age 65 and over, ulcerative colitis, immunosuppression,
and receipt of chemotherapy [5,6]. The last group of high-risk patients is particularly
vulnerable since oncology patients are particularly at risk due to immunosuppression,
broad-spectrum antibiotic use, chemotherapy, and frequent hospitalization, resulting in
significant morbidity and mortality in this population [7]. Additionally, CDI has also been
associated with an increased risk of death and prolonged hospitalization in children [8–11].
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Recent studies have demonstrated that C. difficile strains utilize various exogenous organic
and inorganic iron sources for growth, and mutations within the ferric uptake regulator
gene have been reported to confer metronidazole (MTZ) resistance in C. difficile [12].
Iron is an essential micronutrient for microorganisms and humans. Iron is bound
to protein in the human body, such as heme compounds (hemoglobin), heme enzymes,
or nonheme compounds (ferritin). The body uses iron to form the proteins or enzymes
essential for electron transfer and oxidation–reduction reactions, such as oxygen transport
protein hemoglobin. Since iron is highly bound and conserved to the iron-binding protein
ferritin, serum ferritin level is commonly used to estimate iron stores in the body [13].
Oncology patients have a high risk of iron overload resulting from frequent red blood cell
transfusions [14]. Each infused RBC unit contains approximately 200–250 mg of iron [15].
Iron typically binds to transferrin, an iron storage protein. However, when transferrin is
saturated, free iron circulates in the body and is deposited into tissues. Given the fact that
humans have no physiologic mechanism for excreting excess iron, the unbound free iron
catalyzes the formation of reactive oxygen species, which leads to organ damage [16,17].
Moreover, iron has been shown to stimulate the growth of many pathogenic microorganisms such as Mycobacterium tuberculosis [18,19]. Invading microbes including
Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Salmonella species have developed multiple strategies to utilize iron as a nutrient, resulting in pathogen proliferation
and virulence [20–25]. Recent studies have also demonstrated a significant relationship
between iron overload, infectious complications, and poor prognosis in oncology patients
post-hematopoietic stem cell transplantation. The prevalence of severe infectious events
such as bacteremia, invasive aspergillosis, and mucormycosis was significantly higher in
patients that presented with iron overload [26,27].
In this study, we report that in vitro, excess iron stimulates the growth of C. difficile
and increases the expression of toxin A and B mRNA (tcdA and tcdB). Exposure to excess
iron also leads to metronidazole tolerance, as measured by increasing minimum inhibitory
concentrations (MICs). The iron chelator, deferoxamine (DFO), returned the metronidazole
MIC to baseline and effectively inhibited the growth and toxin production of C. difficile
induced by iron.
2. Results
2.1. Iron Stimulates C. difficile Growth and Toxin Production In Vitro
The effects of Fe3+ on bacterial growth were assessed by colony-forming units (CFUs).
As shown in Figure 1a, a significant increase in CFU/mL after 16 h incubation was evident
in the 9689 strain grown in media supplemented with FeCl3 . The increase in CFU was
observed in the presence of Fe3+ as low as 10 µM (3.5-fold of control) and peaked at 100 µM
in a dose-dependent manner to 13.8-fold of control. Co-incubation with DFO significantly
reduced the CFU in the presence of 50 µM Fe3+ , compared with FeCl3 alone (p < 0.05).
However, the average CFU with DFO and FeCl3 co-treatment remained higher than the
control. The induction of CFU was also evident in the R20291 strain but to a lesser extent
(~1.9-fold of control, Supplementary Figure S1).
The gene expression levels of tcdA and tcdB were also detected by qRT–PCR (Figure 1b) [28]
after iron treatments for 16 h. As shown in Figure 1b, the tcdA and tcdB expression levels
were significantly increased by 50 µM Fe3+ treatment in the 9689 strain, where mRNA levels
of tcdA and tcdB increased to 2.2- and 3.3-fold of the non-treatment control, respectively
(p < 0.05).
After culturing at various concentrations of Fe3+ for 16 h, the bacterial culture supernatants were collected and concentrated using a 3K concentration spin. Equal volumes
of samples were subjected to Western Blot analysis, and the band densities were measured (Figure 1c). The presence of iron increased strain 9689 toxin A production in a
dose-dependent manner, resulting in 2.6-, 3.8-, 5.5-, and 8.6-fold change with concentrations
of 10 µM, 20 µM, 50 µM, and 100 µM of Fe3+ , respectively. However, when normalizing the
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data to CFU, no significant change was observed after Fe3+ treatment, compared with the
control (Figure 1d).

Figure 1. Effects of iron on C. difficile colony formation and production of toxins: (a) the increase in
colony formation units following Fe3+ treatments was suppressed by iron chelator DFO co-treatment
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absence or presence of excess Fe3+ . The C. difficile strains tested included the historical
9689 and the clinical hypervirulent R20291 strains. The 9689 strain is susceptible to MTZ,
while the R20291 strain is MTZ-non-susceptible. In our study, R20291 showed a marked
decrease in the susceptibility to MTZ, and MICs were up to 64 µg/mL under the standard
treatment conditions.
In the presence of excess iron, the MICs of MTZ were significantly increased in
C. difficile strain 9689 (Figure 2a and Supplementary Table S2). After 48 h incubation with
50 µM Fe3+ , the average MIC increased from 0.17 µg/mL to 1.38 µg/mL, and in some
replicates, the MIC was up to 2 µg/mL, which is at the breakpoint indicated by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for MTZ and C. difficile.
The MTZ MICs were highest after co-incubation with 50 µM Fe3+ . Increasing iron concen5 of 14
tration to 100 µM did not increase the MICs any further. In the MTZ-non-susceptible
strain,
R20291, no changes in susceptibility to metronidazole were observed for 24 h or 48 h under
any of the treatment concentrations (Supplementary Table S2).
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Fidaxomicin MICs also significantly increased in the presence of Fe3+. As shown in
Figure 2c, after 24 h incubation, Fe3+ (50 μM) increased the MIC of fidaxomicin to 6.7‐fold
of control in the C. difficile 9689 strain but were still at values <1 μg/mL, which would be
considered susceptible. In strain R20291, there was an eightfold increase in MIC at 48 h
regardless of the presence of iron and an approximately twofold increase under 10 μM
and 50 μM iron concentrations. The fidaxomicin MIC was consistently 1 μg/mL at 24 h
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Treatment of DFO alone effectively reduced colony formation in the C. difficile 9689
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alone
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in thefor
C.16
difficile
strain in a dose‐dependent
manner
(Figure
3b). After
exposure
DFO (50 μM)
h, 9689
strain in a dose-dependent manner (Figure 3b). After exposure to DFO (50 µM) for 16 h,
the CFU reduced to 45.8% of control (p < 0.05). Iron‐induced toxin A production was also
the CFU reduced to 45.8% of control (p < 0.05). Iron-induced toxin A production was
diminished by DFO, with the expression levels of toxin A reduced from 5.2‐fold to 2.1‐
also diminished by DFO, with the expression levels of toxin A reduced from 5.2-fold to
fold of control after DFO co‐treatment (Figure 3c). Consistently, co‐incubation with DFO
2.1-fold of control after DFO co-treatment (Figure 3c). Consistently, co-incubation with
sensitized C. difficile to MTZ treatment and effectively reduced the MICs of MTZ in the
DFO sensitized C. difficile to MTZ treatment and effectively reduced the MICs of MTZ in
presence of excess iron (p < 0.05, Figure 3d).
the presence of excess iron (p < 0.05, Figure 3d).
Finally, to determine if removing free Fe3+ via chelation
with DFO resulted in a rever‐
Finally, to determine if removing free Fe3+ via chelation with DFO resulted in a
sion to baseline susceptibility, strain 9689 was co‐treated with 50 μM DFO and MTZ for
reversion to baseline susceptibility, strain 9689 was co-treated with 50 µM DFO and MTZ
24 h and 48 h. As shown in Figure 3d, the MIC had increased by 3.3‐fold of control after
for 24 h and 48 h. As shown in Figure 3d, the MIC had increased by 3.3-fold of control after
exposure to 50 μM of FeCl3. DFO co‐treatment effectively re‐sensitized C. difficile to MTZ,
exposure to 50 µM of FeCl3 . DFO co-treatment effectively re-sensitized C. difficile to MTZ,
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and the MIC was reduced to control values after 24 h treatment and even lower than that
of control after 48 h treatment.
3. Discussion
Despite the benefits of red blood cell (RBC) transfusion therapy, it renders patients
vulnerable to iron overload [14]. Iron loading from blood transfusions can be estimated
from the total number of units of red blood cells given, with each infused unit of RBCs
containing approximately 200 to 250 mg of iron [15]. The National Comprehensive Cancer
Network (NCCN) Clinical Practice Guideline recommends adjustment for each patient to
maintain the lowest hemoglobin level sufficient to avoid RBC transfusion due to the risk of
iron overload [34].
Iron is an essential co-factor in many reactions and leads to many transcriptional
changes [35]. Under normal conditions, there is typically low iron availability within the
body and serum, as iron is tightly regulated within the host. However, C. difficile and other
bacteria produce siderophores that bind iron in the environment for subsequent uptake
through ABC transporters [36]. In addition, Hastie et al. found that C. difficile growth is less
robust and considerably decreased under iron-limited media than the standard media [37].
Consistently, our study demonstrated that the growth and toxin production of C. difficile
were significantly stimulated by exposure to excess iron. Both observations further confirm
iron’s nutritional role in microorganism growth, also described in other bacteria and fungi
pathogenesis [38,39].
Until recently, the underlying mechanism of C. difficile resistance to metronidazole
was not well defined. An earlier proteomic analysis study using clinical isolates showed
the potential role of iron metabolism in the development of metronidazole resistance [40].
In recent years, Boekhoud et al. discovered the high replication number of pCD-METRO
plasmid in C. difficile isolates that displayed stable and medium-independent resistance to
metronidazole in a large collection of clinical isolates [41]. In our study, we sought to explore
whether the presence of iron in the medium could lead to resistance to metronidazole.
We found that the addition of Fe3+ to growth media at concentrations of 10, 50, and 100 µM
resulted in more than eightfold increases in MICs, compared with control media with no
additional iron supplementation. The most significant increases occurred at 50 µM in both
24 and 48 h time points in strain 9689. While the folds of increase were significant, the MIC
values of MTZ would not be considered resistant as the EUCAST breakpoint is 2 µg/mL,
and the CLSI breakpoint is 32 µg/mL. Thus, iron did not lead to MIC values that would be
classified as resistant. However, such increases observed in our study may still be clinically
relevant. Gonzalez-Luna et al. recently found through classification and regression tree
(CART) analysis that MICs higher than 1 µg/mL were significantly associated with clinical
failure in the treatment of C. difficile [42]. The highly virulent epidemic NAP1/027 C. difficile
strain R20291 exhibited resistance to metronidazole treatment with MICs >64 µg/mL,
independent of media iron supplementation.
During the time of this study, Boekhoud et al. followed up on their medium-independent
metronidazole resistance finding, with a discovery of medium-dependent resistance [43].
Their study found that haem presence in media led to an 8- to 25-fold increase in metronidazole MICs, compared with media without haem. Our results also demonstrate that
when Fe3+ is added to the growth medium, metronidazole MICs increase up to eightfold.
Such observation further supports their finding, as haem is an iron-containing porphyrin
and would thus lead to their observed increase in MICs with haem supplementation.
We further demonstrated that co-treatment with iron chelator DFO effectively obviated the
increase in MTZ MICs in the presence of excess iron. Furthermore, our study suggests that
the increase in MIC induced by iron was specific to metronidazole at 24 h and 48 h in strain
9689 and to fidaxomicin at 24 h and 48 h in both 9689 and R20291; however, vancomycin
MICs were unaffected under the same growth conditions and time points. This observation
is similar to what Boekhoud et al. reported, indicating that, despite haem supplementation
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of growth mediums, no increases in vancomycin MICs were evident, and the effect of haem
was only observed with metronidazole treatment [43].
Finally, we found that, in the presence of excess iron, C. difficile toxin A production was
increasingly measurable by Western Blot, and mRNA levels for tcdA and tcdB were induced
relative to control. The presence of iron increased the measure of toxin A present in media
in a dose-dependent manner. However, when normalizing the data to CFU counts from
aliquots of the cultures before supernatant preparation, no significant change was observed
after Fe3+ treatment, compared with the control (Figure 1d). This result suggests that the
increased levels of toxin A with Fe3+ supplementation were, at least partially, related to
the increased CFU of C. difficile stimulated by Fe3+ . The increase in tcdA and tcdB mRNA
levels observed may also be explained by the increased cell density that resulted from the
iron supplementation, which could have resulted in quorum sensing, leading to the tcdA/B
transcriptional increases observed [44].
In recent years, there has been an increased risk of CDI in patients diagnosed with cancer [45]. This association is likely due to the common use of broad-spectrum antimicrobials
and extensive chemotherapy, both of which can disrupt the gut microbiome. In addition to
the prolonged immunocompromised status in cancer patients, GI toxicities associated with
chemotherapy, such as mucositis, may increase the germination of C. difficile spores and
disease manifestation [46,47]. Given the roles of iron in C. difficile as described above, it is interesting to speculate that the excess iron present in patients with cancer after receiving red
blood cell transfusions may increase the risk of C. difficile infection. The clinical importance
of our findings is that iron can affect the susceptibility of C. difficile strains to metronidazole
and fidaxomicin. Currently, CDI treatment relies on three antibiotics: metronidazole, vancomycin, and fidaxomicin. Vancomycin and fidaxomicin are considered first-line agents in
adults, and in pediatrics, vancomycin or metronidazole are recommended treatments [6,48].
Since metronidazole is a therapeutic option for C. difficile in pediatric patients, it is crucial to
consider the influence of iron overload in the pediatric oncology patient population when
determining the course of treatment for CDI. Moreover, as our study showed that in the
presence of excess iron, the tested C. difficile strains remained susceptible to vancomycin, it
provides the rationale for using vancomycin as the first-line treatment of CDI among these
patients. These observations on susceptibility, coupled with the observation that Fe3+ can
directly increase C. difficile growth and indirectly lead to more potential toxin production
via increased growth, suggests that iron may potentially affect therapeutic outcomes in
specific patient populations with iron overload.
Moreover, iron chelation has been shown to reduce iron-induced tissue toxicity and improve patients’ short- and long-term treatment outcomes [49,50]. In our study, co-treatment
with iron chelator effectively reduced the toxin levels of C. difficile induced by excess iron
and resensitized C. difficile to MTZ. In recent years, the development of novel iron chelators
has attracted more attention as they have shown promising antitumor, antimicrobial, and
cardioprotective activities [51–56]. Deferoxamine has been used as the standard drug for
iron chelation therapy over the past four decades, which requires parenteral administration
and presents with significant adverse effects, such as injection site reaction, hypersensitivity
reactions, and neurological disturbances. The newer generation of oral iron chelators,
such as deferasirox, is more convenient for administration and is suitable for patients with
chronic conditions requiring prolonged iron chelation therapy [57]. However, deferasirox
may cause acute kidney injury requiring dialysis, severe hepatic toxicity, and gastrointestinal hemorrhage, which requires close patient monitoring. The development of safe and
potent iron chelators is greatly warranted, which may also benefit CDI management in
iron-overloaded patients with cancer. Further in vivo studies are warranted to determine
the effects of iron overload and chelation on CDI using an animal model. The role of iron
in persistent and recurrent C. difficile infections among patients with cancer also needs to
be defined.
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4. Materials and Methods
4.1. Bacterial Strains, Culture Conditions, and Growth Analysis
Two different strains of C. difficile were studied: the historic TcdA and TcdB producing
ATCC® 9689™, and PFGE Type NAP1, ribotype 027 strain R20291 (Supplementary Table S1).
ATCC® 9689 was purchased from VWR (Wayne, PA, USA). C. difficile strain R20291
was a kind gift from Dr. Kevin Garey, University of Houston College of Pharmacy,
Houston, TX, USA.
Both C. difficile strains were routinely cultured from frozen glycerol stocks (−80 ◦ C) and
maintained on brain heart infusion (BHI) media (Hardy Diagnostics, Santa Maria, CA, USA)
and agar plates supplemented with 0.5% yeast extract (VWR, Wayne, PA, USA) and 0.1%
L-cysteine (Sigma Aldrich, St. Louis, MO, USA) under anaerobic conditions (85% N2 , 5%
H2 , and 10% CO2 ) in a BACTRON™300 anaerobic chamber (Sheldon Manufacturing Inc.,
Cornelius, OR, USA). Overnight cultures in BHI broth were started using identical starting
inoculation volume and optical density at 600 nm wavelength (OD600) taken using a V-12
Spectrophotometer (VWR).
The growth of C. difficile was determined by the colony-forming units (CFUs). For this,
1 mL aliquots of culture were used for the CFU/mL enumeration. All the growth experiments were performed at least three times.
4.2. Antibiotics, Iron-Chelators and Iron Supplementation
The stocks of metronidazole (MTZ, metronidazole injection 5 mg/mL, Hospira, Lake Forest,
IL, USA) and vancomycin (VAN, vancomycin hydrochloride for injection, Alvogen, Morristown, NJ, USA) were prepared in normal saline. Fidaxomicin (Merck Co.; Kenilworth,
NJ, USA) and the iron chelator deferoxamine (Sigma Aldrich Chemical Co.; St. Louis, MO,
USA) were reconstituted with sterile water. Exogenous iron was added to growth media as
iron (III) chloride (Sigma-Aldrich, St. Louis, MO, USA) in sterile water. All stock solutions
were filter-sterilized (0.22 µm) before use.
4.3. Susceptibility Testing
C. difficile strains were first grown overnight in BHI broth. The susceptibilities to
metronidazole (MTZ) or vancomycin (VAN) were then conducted using the broth microdilution method in 96-well round-bottomed plates. BHI broth cultures were diluted
to 0.5 McFarland turbidity in normal saline, and a 1:150 dilution was used to inoculate
pre-reduced BHI broth. Antibiotic stocks were further diluted in BHI broth with serial
twofold dilutions. Negative and positive controls were tested in parallel. Ferric chloride
was added at final concentrations of 10, 50, and 100 µM into BHI broth to assess the effect
of iron overload on antibiotic susceptibility. In experiments that required an iron chelator,
deferoxamine was added to the media at final a concentration of 50 µM. Then, 125 µL of
prepared C. difficile solution (1:150 dilution) was added to duplicate wells of a 96-well plate
containing 125 µL of twofold serially diluted MTZ, VAN, and fidaxomicin. MIC plates
were incubated anaerobically at 37 ◦ C, and results were read after 24 h and 48 h incubations
using an iMark™ Microplate Reader (Bio-Rad, Hercules, CA, USA). At least three independent experiments with two replicates in each were performed. The MIC was defined as
the lowest concentration of antibiotic that prevented visible and measurable (via optical
density) bacterial growth after 24 h and 48 h.
4.4. Polyacrylamide Gel Electrophoresis (PAGE) and Western Blot Analysis
Iron at various concentrations was added to the bacterial culture to determine the
effects of iron on the levels of C. difficile toxin production. After 16 h incubation, 10 mL
bacterial supernatants were collected, 0.5 mL was used for CFU counting, and the remaining 9.5 mL was centrifuged at 5000× g for 10 min and concentrated 10 times using 3K
MWCO Amicon® Ultra-15 Centrifugal Filter Unit (Sigma-Aldrich, St. Louis, MO, USA).
Equal volumes of clear concentrated supernatants were subjected to SDS–PAGE Western
Blot analysis.
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Samples in 4 × sample buffer (Bio-Rad, Hercules, CA, USA) were separated by SDS–
polyacrylamide (7.5%) gel electrophoresis, followed by transfer onto nitrocellulose membranes (GE Healthcare). After incubation with blocking solution (1 × TBS, 10% non-fat milk,
and 0.1% Tween-20) for 2 h at room temperature, the blocked membrane was incubated
with primary Anti-Clostridium difficile toxin A (PCG4, #ab19953) overnight (4 ◦ C, 1:1000 dilution). Secondary antibodies, anti-mouse-IgG-horseradish peroxidase-linked or anti-rabbit
IgG-horseradish peroxidase-linked whole antibodies (Cell Signaling Technology, Danvers,
MA, USA), were used at a dilution of 1:5000 in blocking solution. Immunoreactive bands
were visualized using the SuperSignal™ West Pico PLUS Chemiluminescent Substrate
(Thermo Fisher Scientific, Waltham, MA, USA) and Bio-Rad Imager (Bio-Rad, Hercules,
CA, USA).
4.5. Chrome Azurol S (CAS) Assay
Antibiotics at different concentrations were subjected to the chrome azurol S (CAS)
assay, a colorimetric method that detects siderophore-iron complexes, performed according
to Schwyn and Neilands (1987) [33]. Briefly, 500 µL of compound dilutions were added
to 500 µL of CAS assay solution (6 mL of 10 mM hexadecyltrimethylammonium bromide
(HDTMA), 1.5 mL of 1 mM FeCl3 , 7.5 mL of 2 mM CAS, 4.307 g of piperazine, and 6.25 mL
of 12 M HCl diluted to 100 mL in deionized water; final pH of 5.6) and incubated for 1 h at
room temperature with gentle mixing. Absorbance spectra for CAS solution–supernatant
mixtures were then measured at 630 nm using a V-12 Spectrophotometer (VWR, Wayne, PA,
USA). Iron chelator DFO and ferrichrome, a siderophore produced by Ustilago sphaerogena,
were positive controls.
4.6. Isolation of RNA and qRT-PCR Assay
Total RNA was isolated from collected bacterial pellets using the using Quick-RNA™
Miniprep kit (Zymo Research, Irvine, CA, USA) according to the manufacturer’s instructions and quantified using Nanodrop. Changes in tcdA and tcdB gene expressions
were assessed by quantitative real-time PCR using methods previously described with
C. difficile 16S rRNA as the internal control. The primers were tcdA-forward, CAACACCTTAACCCAGCCATA; tcdA-reverse, AGAGTTTTCTGCGGTAGCTGA; tcdB-forward,
ATCTGGAGAATGGAAGGTGGT; tcdB-reverse, TGATGGTGCTGAAAAGAAGTG; 16S
rRNA-forward, AGCGGTGAAATGCGTAGATAT; 16S rRNA-reverse, CAG CGTCAGTTACAGTCCAGA [28]. First-strand cDNA was prepared from 500 ng RNA using the
iScriptTM cDNA Synthesis Kit (BioRad; Hercules, CA, USA). cDNA synthesis was carried
out in C1000 Touch™ Thermal Cycler (BioRad) with priming at 25 ◦ C for 5 min, reverse
transcription at 50 ◦ C for 10 min, followed by iScript reverse transcriptase inactivation at
95 ◦ C for 5 min. Quantitative PCR was performed using SsoAdvanced Universal SYBR
Green Supermix (BioRad, Hercules, CA, USA) in CFX96 Touch™ Real-Time PCR Detection
System (BioRad, Hercules, CA, USA). PCR amplification of cDNA (1 µg) was performed
under the following conditions: 95 ◦ C for 10 min; 40 cycles at 95 ◦ C for 15 s, followed
by 55 ◦ C for 60 s. Relative gene expression was determined using the 2−∆∆Ct method.
The sample’s mean value of Ct of 16S rRNA (internal control gene) was subtracted from the
sample mean Ct of the tcdA and tcdB genes (∆Ct), respectively. ∆Ct of the no treatment control was subtracted from the mean ∆Ct of each experimental sample (∆∆Ct). This 2−∆∆Ct
method yields the fold of change in gene expression of the gene of interest normalized to
the expression of the 16S rRNA internal control and relative to the no treatment control.
4.7. Statistical Analysis
Data are presented as numbers and percentages for categorical variables and as means
± standard deviation for continuous variables. Statistical analyses were performed with
t-tests for independent variances. Two-sided p-values of <0.05 were considered significant.
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5. Conclusions
Our study demonstrates that the growth of C. difficile and toxin measured was significantly increased by excess iron. The presence of excess iron also contributed to the
increasing MICs of metronidazole and fidaxomicin. The increase in MICs for metronidazole
was significant for the classic 9689 strain and for fidaxomicin MICS in the hypervirulent
R20291 strain. Using an iron chelator led to a reversal of the observed effects and thus may
serve as a unique strategy for CDI treatment in patients in whom iron overload is suspected
or present.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/antibiotics11050537/s1, Figure S1: Effect of Fe3+ on colony formation units in C. difficile R20291 strain, Table S1: Summary of characteristics of C. difficile strains
used in the study, Table S2: Effects of Fe3+ on the MICs of metronidazole in different C. difficile strains,
Table S3: Effects of Fe3+ on the MICs of vancomycin in different C. difficile strains, Table S4: Effects of
Fe3+ on the MICs of fidaxomicin in different C. difficile strains.
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